The deal, which is expected to be in the range of ₹100 crore, will enable SRF to expand and complement its existing offerings ...

KPL-387 is an independently developed monoclonal ... potential undesirable side effects caused by our products and product candidates; our inability to demonstrate safety and efficacy to the ...

These new products should also substantially extend ... it's worth pointing out the differences between Arcalyst and KPL-387 and KPL-1161. Arcalyst is an interleukin-1α ('alpha') and interleukin ...

KPL-387 is a fully human immunoglobulin G2 ... potential undesirable side effects caused by our products and product candidates; our inability to demonstrate safety and efficacy to the ...

Featuring major events such as League of Legends Worlds 2024, and Demacia Cup, Honor of Kings KPL Grand Finals ... and market performance of future game products are expected to influence the ...

Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig ...

KPL-387 is an independently developed monoclonal antibody that ... potential undesirable side effects caused by our products and product candidates; our inability to demonstrate safety and efficacy to ...